Stryker Corp
SYKNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 19/3024% below fair value
$306.81+14.95 (+5.12%)
Close on Nov 2, 2026Market cap $117.68BP/E 32.7Yield –
Stryker MedSurg & Neurotechnology Segment by Quarter
MedSurg & Neurotechnology Segment — Worldwide Net Sales ($M) ($M)
Stryker MedSurg & Neurotechnology Segment: $3,664M in Q3 2026, up 9.2% from a year earlier.
Latest, Q3 2026
3,664
Period ended Sep 30, 2026
Change on a year earlier
+9.2%
3,355 in Q3 2025
History
18 quarters
Since Q1 2022
Sources
15
Documents cited below
Where the Q3 2026 figure comes from
Reported in Stryker Form 8-K Supplemental Sales Schedules & Recast Form 8-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up medSurg & Neurotechnology Segment
Cite this data
StockData. (2026). Stryker MedSurg & Neurotechnology Segment ($M), quarterly Q1 2022–Q3 2026 [Data set]. Compiled from Stryker SEC filings and investor materials. https://stockdatahq.com/stocks/syk/kpis/ms-tot-ww-rev
See every metric in the Stryker KPI table. Data updated Nov 2, 2026.